



Upcoming Conferences

Rodman & Renshaw 12th Annual Healthcare conference, September 12-15, 2010. New York, NY.

American Heart Association Scientific Meetings, November 13-17, 2010. Chicago, IL.

Resverlogix Analysts

Dr. Simos Simeonidis, Ph.D., Director and Senior Biotechnology Analyst, Rodman & Renshaw

Dr. David Martin, Ph.D., MBA, Analyst, Biotechnology & Healthcare, Dundee Securities Corporation

Mr. Claude Camiré, Biotech & Healthcare Analyst, Paradigm Capital

Market Opportunity

Cardiovascular disease (CVD) is responsible for 30% of deaths worldwide according to the World Health Organization. One person will die every 30 seconds from CVD in the United States alone. The 2010 American Heart Association statistics report estimates roughly 81 million adults in the United States have one or more types of CVD. Drugs for the treatment of cardiovascular disease represent the largest pharmaceutical market opportunity in the world at US \$30-50 billion annually. There exists a huge unmet medical need for new cardiovascular therapies. Future estimates indicate that CVD mortality will increase by 90% by the year 2020 versus rates in 1990. The American Heart Association estimates the direct and indirect costs of CVD in the United States alone are US \$503.2 billion.

About Resverlogix

Resverlogix Corp. (Toronto Stock Exchange: RVX) is a Canadian biotechnology company with a world lead in developing a new class of drugs for cardiovascular disease (CVD). **NexVas™ Plaque Regression (NexVas PR)**, is a novel technology platform with drugs that increase apolipoprotein A-I (ApoA-I) to reduce atherosclerosis (fatty plaque build-up in the arteries), which is the leading cause of CVD. Current drugs on the market only manage atherosclerosis burden but they have very limited or no effect on atherosclerosis regression. NexVas PR aims to manage and regress atherosclerosis. Resverlogix's lead ApoA-I drug **RVX-208** recently completed a Phase 2 clinical trial, named ASSERT which was conducted by Cleveland Clinic

Resverlogix Corp. trades on the Toronto Stock Exchange under the symbol RVX.

www.resverlogix.com

AGM Notice

September 9, 2010

Telus Convention Centre, Calgary, AB

Rooms Glen 201 & 202

2:00 pm Mountain time

Recent News

Scientific Data Presented at ESC Congress in Stockholm, Sweden

September 1, 2010—Resverlogix imparted data in an oral presentation titled, "RVX-208: a small molecule given orally raises ApoA-I/HDL in human clinical trials and reduces plaque numbers in an ApoE null mouse model of atherosclerosis". In summary, RVX-208 raises plasma HDL in ApoE null mice and in so doing lowers atherosclerotic plaque number in the aorta of treated mice. The Phase 1b/2a clinical trial demonstrated the ability of RVX-208 to increase ApoA-1/HDL in humans and identify a therapeutic range of RVX-208 that is safe and well tolerated through 28 days of treatment. The finding of ApoA-1 and HDL being higher at 28 vs. 8 day points to a time dependent rise in these parameters.

Scientific Data Presented at EAS Congress in Germany

June 22, 2010- Resverlogix Corp. announced that key scientific data was communicated in an oral presentation highlighting the novel features of the Company's lead drug RVX-208 at the European Atherosclerosis Society Congress (EAS) conference. The presentation titled "RVX-208 given orally raises plasma ApoA-1 and HDL in human clinical trials," was presented by Dr. Norman Wong, MD, Chief Scientific Officer of Resverlogix.

"The data presented in Germany today further highlights that patients with low HDL/ApoA-1 benefit most. For those patients in the highest risk category, subjects with low baseline HDL/ApoA-1, our data demonstrated that RVX-208 increased plasma levels of ApoA-1 in the order of 13.25% compared to placebo. This data, combined with similar low baseline HDL/ApoA-1 data analysis of the upcoming ASSERT trial data will further support the design of a very effective and efficient ASSURE trial," said Donald J. McCaffrey, President & CEO of Resverlogix.

Resverlogix Closes CDN \$10 Million Financing

June 22, 2010- Resverlogix announced that it has closed its previously announced prospectus offering of 3.1 million units at a price of CDN \$3.23 per Unit for gross proceeds of \$10 million. Each Unit was comprised of one common share of the Company and 0.4 of a common share purchase warrant. Each full warrant is exercisable at a price of CDN \$4.00 for a period of four years.

Resverlogix Closes CDN \$9.2 Million Financing

June 8, 2010- Resverlogix announced that it has closed its previously announced prospectus offering of 2.8 million units at a price of CDN \$3.30 per Unit for gross proceeds of \$9.2 million. Each Unit was comprised of one common share of the Company and 0.4 of a common share purchase warrant. Each full warrant is exercisable at a price of CDN \$4.00 for a period of four years.



ERROR: undefined
OFFENDING COMMAND: f'~

STACK: